z-logo
open-access-imgOpen Access
Deep Learning Reveals Cancer Metastasis and Therapeutic Antibody Targeting in the Entire Body
Author(s) -
Chenchen Pan,
Oliver Schoppe,
Arnaldo ParraDamas,
Ruiyao Cai,
Mihail Ivilinov Todorov,
Gábor Gondi,
Bettina von Neubeck,
Nuray Böğürcü,
Sascha Seidel,
Katia Sleiman,
Christian Veltkamp,
Benjamín Förstera,
Hongcheng Mai,
Zhouyi Rong,
Omelyan Trompak,
Alireza Ghasemigharagoz,
Madita Alice Reimer,
Ángel M. Cuesta,
Javier Coronel,
Irmela Jeremias,
Dieter Saur,
Amparo AckerPalmer,
Till Acker,
Boyan K. Garvalov,
Bjoern Menze,
Reinhard Zeidler,
Ali Ertürk
Publication year - 2019
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2019.11.013
Subject(s) - metastasis , cancer , monoclonal antibody , biology , pancreatic cancer , antibody , cancer research , breast cancer , cancer cell , deep learning , computational biology , immunology , artificial intelligence , computer science , genetics
Reliable detection of disseminated tumor cells and of the biodistribution of tumor-targeting therapeutic antibodies within the entire body has long been needed to better understand and treat cancer metastasis. Here, we developed an integrated pipeline for automated quantification of cancer metastases and therapeutic antibody targeting, named DeepMACT. First, we enhanced the fluorescent signal of cancer cells more than 100-fold by applying the vDISCO method to image metastasis in transparent mice. Second, we developed deep learning algorithms for automated quantification of metastases with an accuracy matching human expert manual annotation. Deep learning-based quantification in 5 different metastatic cancer models including breast, lung, and pancreatic cancer with distinct organotropisms allowed us to systematically analyze features such as size, shape, spatial distribution, and the degree to which metastases are targeted by a therapeutic monoclonal antibody in entire mice. DeepMACT can thus considerably improve the discovery of effective antibody-based therapeutics at the pre-clinical stage. VIDEO ABSTRACT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom